Fresh News Friday: DMC, OneOme, and Ethanol Co-ops

Here are the top news stories from around the web from Rochester’s entrepreneurial and small business scene.

  1. Noseworthy: Mayo Clinic on Schedule to Meet DMC Developmental Targets- The Med City Beat. The Mayo Clinic CEO announced that the company is on track to deliver their DMC target funds. Over the next two decades, Mayo Clinic will invest $3.5B toward DMC projects. DMC is on track to receive $200M in private investment by the end of the year.
  2. Rochester Airport Keeps International Flights with $7.3M Upgrade- StarTribune. The Rochester International Airport faced a potential downgrade to municipal airport status when U.S. Customs and Border Protection found the airport’s customs facility to be outdated. The airport recently scored $7.3M in a U.S. Department of Transportation grant to upgrade the customs facility. Maintaining status as an international airport is essential to support the DMC initiative and the future of international business in Rochester.
  3. Claremont, MN Awarded a $500,000 CEDA Authored Business Development Public Infrastructure Grant- Community and Economic Development Associates. Claremont recently received a $500K grant for street improvements to aid in a $146M expansion of Al-Corn Clean Fuel, a farmer-owned ethanol production co-op. Three hundred construction jobs are expected to be generated for the buildout.
  4. Winners of the 2016 Manufacturing Awards by Minnesota Business Magazine- Minnesota Business Magazine. This week, Minnesota Business Magazine honored top manufacturers in the state with their 2015 Manufacturing Awards. Manufacturing contributes $37B to the state economy. Blooming Prairie based Minimizer was a finalist in the mid-sized company category this year. Minimizer is a leader in poly semi-truck fender manufacture.
  5. OneOme Lands $5.25 Million in Financing Round- Twin Cities Business. The life science startup OneOme is backed by Mayo Clinic and Invenshure, a Minneapolis incubator and venture investor. OneOme uses DNA analysis and their software product, RightMed, to minimize adverse drug reactions in patients. OneOme currently has twenty-five employees.